SAN DIEGO--( BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its financial results for the first quarter ended March 31, 2018.
ACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться